

# A childhood acute lymphoblastic leukemia genome-wide association study identifies novel sex-specific risk variants

Sandeep K. Singh, PhD<sup>a,b</sup>, Philip J. Lupo, PhD<sup>c</sup>, Michael E. Scheurer, PhD<sup>d</sup>, Anshul Saxena, MPH<sup>e</sup>, Amy E. Kennedy, PhD<sup>f</sup>, Boubakari Ibrahimou, PhD<sup>g</sup>, Manuel Alejandro Barbieri, PhD<sup>b</sup>, Ken I. Mills, PhD<sup>h</sup>, Jacob L. McCauley, PhD<sup>i</sup>, Mehmet Fatih Okcu, MD, MPH<sup>d</sup>, Mehmet Tevfik Dorak, MD, PhD<sup>j,\*</sup>

## Abstract

Childhood acute lymphoblastic leukemia (ALL) occurs more frequently in males. Reasons behind sex differences in childhood ALL risk are unknown. In the present genome-wide association study (GWAS), we explored the genetic basis of sex differences by comparing genotype frequencies between male and female cases in a case-only study to assess effect-modification by sex.

The case-only design included 236 incident cases of childhood ALL consecutively recruited at the Texas Children's Cancer Center in Houston, Texas from 2007 to 2012. All cases were non-Hispanic whites, aged 1 to 10 years, and diagnosed with confirmed B-cell precursor ALL. Genotyping was performed using the Illumina HumanCoreExome BeadChip on the Illumina Infinium platform. Besides the top 100 statistically most significant results, results were also analyzed by the top 100 highest effect size with a nominal statistical significance ( $P < 0.05$ ).

The statistically most significant sex-specific association ( $P = 4 \times 10^{-6}$ ) was with the single nucleotide polymorphism (SNP) rs4813720 (*RASSF2*), an expression quantitative trait locus (eQTL) for *RASSF2* in peripheral blood. rs4813720 is also a strong methylation QTL (meQTL) for a CpG site (cg22485289) within *RASSF2* in pregnancy, at birth, childhood, and adolescence. cg22485289 is one of the hypomethylated CpG sites in ALL compared with pre-B cells. Two missense SNPs, rs12722042 and 12722039, in the *HLA-DQA1* gene yielded the highest effect sizes (odds ratio [OR]  $\sim 14$ ;  $P < 0.01$ ) for sex-specific results. The *HLA-DQA1* SNPs belong to *DQA1\*01* and confirmed the previously reported male-specific association with *DQA1\*01*. This finding supports the proposed infection-related etiology in childhood ALL risk for males. Further analyses revealed that most SNPs (either direct effect or through linkage disequilibrium) were within active enhancers or active promoter regions and had regulatory effects on gene expression levels.

Cumulative data suggested that *RASSF2* rs4813720, which correlates with increased *RASSF2* expression, may counteract the suppressor effect of estrogen-regulated miR-17-92 on *RASSF2* resulting in protection in males. Given the amount of sex hormone-related mechanisms suggested by our findings, future studies should examine prenatal or early postnatal programming by sex hormones when hormone levels show a large variation.

**Abbreviations:** ADAM28 = ADAM metalloproteinase domain 28, ALL = acute lymphoblastic leukemia, ARID5B = AT rich interactive domain 5b, BCM = Baylor College of Medicine, CI = confidence interval, eQTL = expression quantitative trait locus, ER = estrogen receptor, ERCC1 = excision repair cross-complementation group 1, FDR = false discovery rate, FIU = Florida International University, GSEA = gene set enrichment analysis, GWAS = genome-wide association study, H3K27ac = histone-3 lysine-27acetylation, H3K4me1 = histone-3 lysine-4 monomethylation, H3K4me3 = histone-3 lysine-4 trimethylation, H3K9ac = histone-3 lysine-9 acetylation, HLA-DQA1 = major histocompatibility complex, class II, DQ alpha 1, HWE = Hardy-Weinberg equilibrium, IFNG = interferon gamma, IRF1 = interferon regulatory factor 1, KAT7 = K(lysine) acetyltransferase 7, LD = linkage disequilibrium, meQTL = methylation quantitative trait locus, MILE study = The Microarray Innovations in Leukemia study, NF = nuclear factor, OR = odds ratio, QC = quality control, QQ = quantile-quantile, RAP1GAP2 = RAP1 GTPase activating protein 2, *RASSF2* = Ras association

Editor: Daryle Wane.

This work has been supported by funds from the Robert Stempel College of Public Health and Social Work, Florida International University.

The authors have no conflicts of interest to disclose.

Supplemental Digital Content is available for this article.

<sup>a</sup> Department of Environmental and Occupational Health, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL,

<sup>b</sup> Department of Biological Sciences, Florida International University, Miami, FL, <sup>c</sup> Department of Pediatrics, Section of Hematology-Oncology, Texas Children's Cancer Center, <sup>d</sup> Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX, <sup>e</sup> Department of Health Promotion and Disease

Prevention, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL, <sup>f</sup> Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, Bethesda, MD, <sup>g</sup> Department of Biostatistics, Robert Stempel College of Public Health and Social Work, Florida

International University, Miami, FL, <sup>h</sup> Centre for Cancer Research and Cell Biology (CCRCB), Queen's University Belfast, Belfast, UK, <sup>i</sup> Dr. John T. Macdonald Foundation, Department of Human Genetics, John P. Hussman Institute for Human Genomics, Biorepository Facility, Center for Genome Technology University of Miami, Miller School of Medicine, <sup>j</sup> Department of Epidemiology, Robert Stempel College of Public Health and Social Work, Florida International University, Miami, FL.

\* Correspondence: Mehmet Tevfik Dorak, School of Health Sciences, Liverpool Hope University, Liverpool, L16 9JD, UK (e-mail: dorakm@hope.ac.uk).

Copyright © 2016 the Author(s). Published by Wolters Kluwer Health, Inc. All rights reserved.

This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.

Medicine (2016) 95:46(e5300)

Received: 6 June 2016 / Received in final form: 27 September 2016 / Accepted: 11 October 2016

<http://dx.doi.org/10.1097/MD.0000000000005300>

domain family member 2, SCAN = SNP and copy number annotation, SNP = single nucleotide polymorphism, TFBS = transcription factor binding sites, TXCCC = Texas Children's Cancer Center, US = United States.

**Keywords:** acute lymphoblastic leukemia, case-only study, effect modification, expression quantitative trait loci, gene expression regulation, genome-wide association study, sex-specific association

## 1. Introduction

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy, with an annual incidence rate of 42 cases per million children under age 15 in the United States.<sup>[1]</sup> While overall 5-year survival rate has improved to 80% on average, the US annual incidence rate increased by 0.8% per year from 1975 to 2012 in children aged 14 years and younger.<sup>[1,2]</sup> Like many other diseases and cancers, childhood ALL risk shows consistent sex differences.<sup>[1,3–5]</sup> Males show a higher incidence rate in comparison to females (45 cases per million children versus 39 cases per million children per year, respectively) in the United States.<sup>[1]</sup> Relapse and secondary malignancies are also more common in males.<sup>[6]</sup> Reasons underlying sex differences in childhood ALL risk are still unknown, as it has not been extensively evaluated.<sup>[4]</sup>

The sex difference in susceptibility to complex disorders is an active research area, and some progress has been made in recent years.<sup>[7,8]</sup> Studies that examined sex differential for etiological clues identified several sex-specific genetic markers also for childhood ALL risk.<sup>[9–14]</sup> For example, a study that examined previously identified childhood ALL single nucleotide polymorphisms (SNPs) in genome-wide association studies (GWAS)<sup>[15,16]</sup> reported sex-specific effects of 2 statistically correlated *ARID5B* (AT-rich interactive domain 5b) SNPs (rs10994982 [ $P=0.01$ ] and rs10740055 [ $P=0.03$ ]), with ALL risk in males (odds ratio [OR]=3.79 and OR=4.35, respectively; ORs for females=1.03 and 1.37, respectively).<sup>[12]</sup> Candidate gene studies have also reported sex differences in genetic associations in childhood ALL. Two SNPs in *ERCC1* (excision repair cross-complementation group 1) are associated with childhood ALL risk among males, but not with females.<sup>[13]</sup> Likewise, several multiple sclerosis risk markers, such as *HLA-DRA* (rs3135388), *HLA-C* (rs9264942), *HSPA1B* (rs1061581), and *IFNG* (rs2069727), also yielded sex-specific associations with childhood ALL risk.<sup>[10]</sup> Associations with an intronic SNP (rs12203592) in *IRF4* and an intergenic SNP (rs2395185) near *HLA-DRA* further suggest the existence of sex-specific genetic risk variants.<sup>[9,11]</sup>

The robust and replicated sex-specific association with an *IFNG* (interferon gamma) polymorphism (rs2069727;  $P_{\text{interaction}}=0.008$ ) in asthma suggests the existence of genetic contribution to sex differences in nonmalignant childhood disorders.<sup>[17]</sup> The same SNP also shows a sex-specific association with childhood ALL risk.<sup>[10]</sup> A recent genome-wide meta-analysis of asthma revealed sex-specific candidate risk markers in interferon regulatory factor 1 (*IRF1*) and RAP1 GTPase activating protein 2 (*RAP1GAP2*) with regulatory effects in gene regulation as expression quantitative trait loci (eQTL).<sup>[18]</sup> Yao et al.<sup>[19]</sup> examined 11,672 disease-associated polymorphisms from the National Human Genome Research Institute GWAS catalog and dbGaP database in relation to gene expression levels in the whole blood derived RNA and identified 14 sex-specific eQTLs. A recent survey of correlations between SNPs and gene expression levels by sex showed that up to 15% of autosomal SNPs have a gender bias in their correlations.<sup>[20]</sup> Similarly, another study reported that 582 autosomal genes have sex-specific differences

in their expression levels.<sup>[21]</sup> Such sex-specific signals are likely to be diluted or cancelled out when both genders are analyzed simultaneously. Likewise, reanalysis of GWAS datasets revealed that coronary artery diseases, Crohn disease, rheumatoid arthritis, and type1 diabetes show sex-specific associations with increased risk in only 1 gender.<sup>[22,23]</sup> In the present GWAS, we explored the genetic basis of sex differences by comparing genotype frequencies between male and female cases with childhood ALL using a case-only study design.

## 2. Materials and methods

### 2.1. Study design

We used a case-only design because of its greater statistical power in detecting effect modification, in this case, sex and genotype interactions, in comparison to other traditional epidemiological designs.<sup>[24]</sup> An assumption of the case-only design requires genotype and sex to be independent in the healthy population. There is no reason to believe that healthy male and female controls have different genotype frequencies in autosomal chromosomes. Recruitment of cases in a rare disease like childhood ALL is a challenge; hence, preferring a statistically more powerful research design was more practical.

### 2.2. Subject recruitment

Institutional review board approval was granted by Florida International University (FIU), Office of Research Integrity, and Baylor College of Medicine (BCM) prior to the study. Samples for the current study were obtained from a parent case-control study of childhood ALL and has been explained elsewhere in detail.<sup>[11]</sup> Briefly, incident cases of childhood ALL were consecutively recruited at the Texas Children's Cancer Center (TXCCC), BCM, in Houston, Texas from 2007 to 2012. The present study used 236 cases from the parent study for the case-only analysis. They were all non-Hispanic whites, aged 1 to 10 years, and diagnosed with confirmed B-cell precursor ALL. Genomic DNA was extracted from blood samples at TXCCC, BCM. Established childhood ALL risk associations identified in previous GWAS<sup>[14–16]</sup> have been replicated to validate the parent case-control study sample using TaqMan allelic discrimination assays at FIU.<sup>[11]</sup>

### 2.3. Genotyping

Genotype data were generated using the Illumina HumanCoreExome BeadChip (Illumina, San Diego, CA) on the Illumina Infinium platform at the John P. Hussman Institute of Human Genomics, University of Miami, Florida.

### 2.4. Data analysis

Quality control (QC) steps were performed in a hierarchical fashion using PLINK and R packages.<sup>[25]</sup> Sample QC was done prior to SNP QC. The Hardy-Weinberg equilibrium (HWE) test was used retrospectively in the whole group of subjects for

sex-specific analysis. Unconditional logistic regression was used to calculate allelic ORs and 95% confidence intervals (CIs) after coding males as cases and females as controls. The coding of male and female cases for statistical analysis meant that an OR greater than 1.0 indicates greater risk for males compared with females. Power analysis and sample software was used to calculate statistical power for various risk genotype frequencies. The study was statistically powered to detect qualitative interactions, that is sex-specific associations differing in direction (risk or protection); rather than associations in the same direction and differing in magnitude (quantitative interactions). Permutation testing (10,000 permutations) was performed for all sex-specific results to rule out chance findings using a threshold of  $P < 0.05$ . Results were adjusted for potential population stratification using the genomic control method.<sup>[26]</sup> A quantile-quantile (Q-Q) plot was used to rule out systematic errors (Supplementary Figure 1, <http://links.lww.com/MD/B374>). Besides the top 100 statistically most significant results (Supplementary Table 1, <http://links.lww.com/MD/B375>), results were also analyzed by the OR with a nominal statistical significance ( $P < 0.05$ ) (Supplementary Table 2, <http://links.lww.com/MD/B376>).

### 2.5. Bioinformatic analysis

To functionally annotate the SNPs that have shown sex-specific associations, a number of bioinformatic tools were used. Variants were annotated for their effects on the gene expression, protein, and the predicted function using several bioinformatic and empirical tools. ANNOVAR was used to obtain functionality scores (DANN, FATHMM, GWAVA, SIFT, PolyPhen2, Mutation Taster, Mutation Assessor, LRT, FATHMM, and MetaLR), as well as conservation scores.<sup>[27]</sup> ANNOVAR and SNPnexus<sup>[28]</sup> were used to predict the effect of variants on transcription factor binding sites (TFBS), microRNA binding sites and identification of variants that disrupt enhancers, repressors, and promoters. Complementary annotations were performed using CADD,<sup>[29]</sup> RegulomeDB,<sup>[30]</sup> HaploReg v4,<sup>[31]</sup> SNI PA,<sup>[32]</sup> and rVarBase.<sup>[33]</sup> GWAS3D was used to predict genetic variants or variants in linkage disequilibrium (LD) affecting regulatory pathways and essential disease/trait associations by integrating functional genomics, chromatin state, sequence motif, and conservation information.<sup>[34]</sup> It also provides visualization tools to comprehend the results. To assess correlations of SNPs with gene expression levels in peripheral blood cells, we used SNP and Copy Number Annotation (SCAN) database<sup>[35]</sup> and Blood eQTL<sup>[36]</sup> databases. For each SNP, the Blood eQTL database and SCAN provided information from experimental data on gene expression

regulation in peripheral blood cells and lymphoblastoid cell lines, respectively. Likewise, we screened mQTLdb for methylation-QTLs (meQTL) to examine effects of sex-specific variants on CpG islands<sup>[37]</sup> at birth, during childhood and adolescence as well as during pregnancy. Statistically similar (proxy) SNP sets for each SNP were obtained from HaploReg v4,<sup>[31]</sup> and were submitted to the tools listed above for a number of analyses. For direct observation of TFBSs nearby SNPs, we examined the Swiss Regulon browser.<sup>[38]</sup> Gene set enrichment analysis (GSEA) was performed using DAVID v6.7.<sup>[39]</sup> The interactions of candidate genes with other genes and noncoding RNAs were investigated using NPinter v3.0,<sup>[40]</sup> which provides experimental data. Computational miRNA targets on protein-coding genes were explored using TargetScan.<sup>[41]</sup> To map the *HLA-DQA1* SNPs to *HLA-DQA1* types, we examined complete sequences of *HLA-DQA1* alleles in the IPD-IMGT/HLA Database (<http://www.ebi.ac.uk/ipd/imgt/hla>).

### 2.6. The microarray innovations in leukemia (MILE) study

The MILE study generated microarray-based gene expression profiles from 2096 patients with standard subtypes of acute and chronic leukemia (and myelodysplastic syndromes) in 11 laboratories on 3 continents.<sup>[42]</sup> The aim of the study was to examine gene expression profiles for diagnosis and subclassification. The individual level data from the 2096 patients were available to compare expression levels of different genes of interest in different leukemia subtypes.

## 3. Results

After stringent QC, 209 subjects and 271,069 SNPs were included in the statistical analysis. In the final dataset, genotype call rates were  $>99.9\%$ . All QC steps and their results are reported in Table 1. The final sample included 116 males (55.5%) and 93 females (44.5%) with no statistically significant difference in age distribution ( $P = 0.43$ ). The mean age was 4.45 ( $\pm 2.58$ ) years for males and 4.73 ( $\pm 2.32$ ) years for females. The genomic inflation factor ( $\lambda$ ), an indicator of population stratification, was 1.0, which suggested no population stratification, as confirmed by the Q-Q plot (Supplementary Figure 1, <http://links.lww.com/MD/B374>). The design was ideal to detect sex-specific associations as the reflection of allele frequencies higher in one sex than the other. Naturally, the allele frequencies in the pooled sample would be in between sex-specific frequencies. We checked this assumption by using the frequencies for the European sample in the HapMap project (Tables 2 and 3). At least for the higher

**Table 1**

#### Quality control steps for samples and SNPs.

	QC steps	Criteria for QC	Numbers filtered
Sample	Sex discordant	We used genetically identified sex information based on sex chromosomes instead of reported sex information	5
	Sample call rate	Call rate $\leq 99\%$	14
	Heterozygosity rate	Autosomal heterozygosity rate outside of $\pm 3$ standard deviations from the mean	8
	Duplicate	Samples excluded as duplicate (PI_HAT $> 90\%$ )	0
SNP	Genotype call rate	Call rate $< 99\%$	6261
	MAF	MAF $\leq 0.03$	260,641*
	Missingness between males and females	Differential missingness between males and females with $P < 1.0 \times 10^{-3}$	478
	HWE	HWE ( $P < 10^{-3}$ ) was used in the whole group	0

HWE = Hardy-Weinberg equilibrium, MAF = minor allele frequency, QC = quality control, SNP = single nucleotide polymorphism.

\* These SNPs had very low allele frequencies and would be noninformative as they show little variation in the sample set being analyzed. Statistical power to detect associations with them was insufficient.

**Table 2****SNPs associated with sex-specific childhood ALL risk at the significance level  $P < 10^{-4}$ .**

SNP	Gene/region	Chr	Minor allele	Location	MAF (males)	HapMap CEU MAF	MAF (females)	OR <sub>allele</sub> (95% CI)*	P value <sup>†</sup>	P value (permutation) <sup>‡</sup>
rs4813720	<i>RASSF2</i>	20	A	Intron	0.23	0.37	0.44	0.30 (0.18–0.50)	$3.85 \times 10^{-6}$	$1.0 \times 10^{-4}$
rs231237	<i>HSPB6/PROSER3</i>	19	A	Intron	0.42	0.39	0.21	3.02 (1.87–4.89)	$6.79 \times 10^{-6}$	$1.0 \times 10^{-4}$
rs7323018	13q14.11	13	G	Intergenic	0.17	0.32	0.36	0.30 (0.18–0.51)	$7.42 \times 10^{-6}$	$1.0 \times 10^{-4}$
rs17027254	2p22.1	2	T	Intergenic	0.19	0.40	0.40	0.36 (0.23–0.58)	$1.66 \times 10^{-5}$	$1.0 \times 10^{-4}$
rs798292	<i>MAGI2</i>	7	G	Intron	0.16	0.24	0.35	0.38 (0.24–0.60)	$4.47 \times 10^{-5}$	$1.0 \times 10^{-4}$
rs13107783	4p15.31	4	A	Intergenic	0.32	0.51	0.52	0.40 (0.26–0.62)	$5.21 \times 10^{-5}$	$1.0 \times 10^{-4}$
rs7912381	10q26.3	10	G	Intergenic	0.39	0.32	0.21	2.71 (1.67–4.51)	$5.47 \times 10^{-5}$	$2.0 \times 10^{-4}$
rs206457	18p11.22	18	T	Intergenic	0.59	0.43	0.38	2.30 (1.53–3.45)	$6.31 \times 10^{-5}$	$1.0 \times 10^{-4}$
rs7723568	5p15.33	5	A	Intergenic	0.35	0.30	0.17	2.77 (1.68–4.56)	$6.66 \times 10^{-5}$	$1.0 \times 10^{-4}$
rs1849374	12p11.22	12	A	Intergenic	0.44	0.29	0.25	2.49 (1.59–3.92)	$7.20 \times 10^{-5}$	$2.0 \times 10^{-4}$
rs506389	8q22.3	8	A	Intergenic	0.28	0.19	0.11	3.00 (1.74–5.17)	$7.99 \times 10^{-5}$	$2.0 \times 10^{-4}$
rs349714	3p25.3	3	T	Intergenic	0.45	0.50	0.26	2.45 (1.57–3.83)	$8.60 \times 10^{-5}$	$1.0 \times 10^{-4}$

ALL = acute lymphoblastic leukaemia, CEU = European sample in HapMap project, Chr = chromosome, MAF = minor allele frequency, SNP = single nucleotide polymorphism.

\* Interaction odds ratio per allele (OR<sub>allele</sub>) for the additive model.

† P value adjusted for genomic control.

‡ P value permutation = point-wise P value from maxT permutation analysis after 10,000 permutation.

ranking results, HapMap frequencies were between the frequencies observed in male and female cases.

When results were ranked according to their P values, the smallest P value was  $3.8 \times 10^{-6}$  for *RASSF2* (Ras association domain family member 2), rs4813720 association, OR<sub>interaction</sub> = 0.30 indicating males with the minor allele were less likely to develop ALL compared with females with the minor allele (Table 2 and Supplementary Table 1, <http://links.lww.com/MD/B375>). The SNP rs4813720 correlates with *RASSF2* expression levels ( $P = 2.1 \times 10^{-6}$ ) in peripheral blood cells<sup>[36]</sup> (Supplementary Table 3, <http://links.lww.com/MD/B377>). Bioinformatic analysis also yielded high functionality scores (CADD = 5.13; DANN = 0.7). According to rVarBase analysis, this SNP maps to active enhancers in highly relevant cell types: primary hematopoietic cells, primary B cells, primary T-helper cells, primary neutrophils, and monocytes. HaploReg v4 analysis revealed that a nearby (552 bp away) SNP, rs7271897, is in LD with rs4813720 ( $r^2 = 0.70$ ), and alters an estrogen receptor (ER)-alpha binding site. Likewise, rs13045004 (within 3 kb) is in LD with rs4813720 ( $r^2 = 0.70$ ), and alters an NF-kB binding site. In HaploReg analysis, there were 3 SNPs in strong LD ( $r^2 \geq 0.80$ ) with rs4813720, but most bioinformatic analyses predicted rs4813720 as the putative causal SNP. An indel SNP rs3215695

was statistically correlated ( $r^2 = 0.98$ ) with rs4813720 yielding a high functional score (2b) for RegulomeDB. This SNP is also located in an active transcription start site.

Having observed that the statistically most significant association (*RASSF2* rs4813720) was likely to be causal, we performed extended in silico analysis of rs4813720. Besides being an eQTL for *RASSF2* in peripheral blood cells, this SNP is also located within enhancers in cell types relevant to leukemia. Since *RASSF2* is frequently methylated in tumors,<sup>[43]</sup> we also examined whether rs4813720 is a meQTL. Screening of the mQTLdb showed that rs4813720 is a very strong meQTL for the CpG site cg22485289 (Table 4) in the promoter region of *RASSF2* at most time points examined (pregnancy, birth, childhood, and adolescence;  $P \leq 9 \times 10^{-14}$ ), and at middle age, but not as significantly ( $P = 2 \times 10^{-10}$ ).

Having established that our top hit rs4813720 is an eQTL for *RASSF2* and a meQTL for a CpG site within the same gene, we examined whether it may be involved in any other mechanism that would affect the expression levels of *RASSF2*. The examination of the NPinter database revealed that *RASSF2* physically interacts with mir-19a/19b. TargetScan also predicts mir-19b binding to *RASSF2* 3'UTR. However, none of the SNPs in the statistically similar SNP set of rs4813720 were within the

**Table 3****SNPs with the highest effect sizes (OR > 10; P < 0.05) showing sex-specific associations with childhood ALL risk.**

SNP	Gene/region	Chr	Minor allele	Location	MAF (males)	HapMap CEU MAF	MAF (females)	OR <sub>allele</sub> (95% CI)*	P value <sup>†</sup>	P value (permutation) <sup>‡</sup>
rs12722042	<i>HLA-DQA1</i>	6	G	Exon	0.07	0.04	0.005	14.72 (1.91–113.2)	0.008	$6.0 \times 10^{-4}$
rs11992342	<i>ADAM28</i>	8	T	Intron	0.07	0.04	0.005	14.72 (1.91–113.9)	0.01	0.001
rs12722039	<i>HLA-DQA1</i>	6	A	Exon	0.07	0.04	0.005	14.08 (1.84–107.5)	0.009	$5.0 \times 10^{-4}$
rs80040922	<i>UMODL1</i>	21	A	Exon	0.06	0.04	0.005	13.66 (1.77–105.5)	0.01	0.001
rs61753605	<i>PRIM2</i>	6	C	Exon	0.06	0.02	0.005	13.37 (1.73–103.2)	0.01	0.002
rs35665085	<i>CECR5</i>	22	G	Exon	0.06	0.05	0.005	12.63 (1.63–97.92)	0.02	0.003
rs143021649	<i>CNTN3</i>	3	T	Exon	0.06	0.04	0.005	11.61 (1.49–90.50)	0.02	0.003
rs6795524	<i>PROS1</i>	3	G	Intron	0.05	0.006	0.005	10.62 (1.35–83.22)	0.02	0.008
rs10003468	4q28.1	4	C	Intergenic	0.05	0.02	0.005	10.62 (1.35–83.22)	0.02	0.006

ALL = acute lymphoblastic leukaemia, CEU = European sample in the HapMap project, Chr = chromosome, MAF = minor allele frequency, OR = odds ratio, SNP = single nucleotide polymorphism.

\* Interaction odds ratio per allele (OR<sub>allele</sub>) for the additive model.

† P value adjusted for genomic control.

‡ P value permutation = point-wise P value from maxT permutation analysis after 10,000 permutation.

**Table 4**

**SNPs with sex-specific associations, their meQTL status (for childhood period) and target CpG sites,<sup>[37]</sup> and the status of DNA methylation in ALL and healthy pre-B cells.<sup>[50]</sup>**

SNP	Target CpG ID (Gene)	P value *	meQTL effect size (regression beta value)	ALL mean methylation	pre-B cells mean methylation	DNA methylation status in ALL	Genetic association effect size (odds ratio)
rs4813720 <sup>†</sup>	cg22485289 ( <i>RASSF2</i> )	$8.3 \times 10^{-23}$	0.432	0.279	0.764	Hypomethylation	0.30
rs8106959 <sup>†</sup>	cg14120049 ( <i>HSPB6</i> )	$6.6 \times 10^{-21}$	0.867	0.651	0.344	Hypermethylation	2.95
rs11708505 <sup>†</sup>	cg24363020 ( <i>SHQ1</i> )	$1.4 \times 10^{-60}$	0.591	0.505	0.873	Hypomethylation	0.48
rs7407281 <sup>†</sup>	cg11957475 ( <i>PMAIP1</i> )	$8.4 \times 10^{-16}$	0.420	0.883	0.600	Hypermethylation	2.70
rs11011225 <sup>†</sup>	cg25427524	$5.1 \times 10^{-15}$	-0.453	ND	ND	ND	.
rs11011225 <sup>†</sup>	cg02535924	$1.6 \times 10^{-15}$	0.472	ND	ND	ND	.
rs719569 <sup>†</sup>	cg02535924	$1.6 \times 10^{-89}$	0.775	ND	ND	ND	.
rs719569 <sup>†</sup>	cg25427524	$3.7 \times 10^{-71}$	-0.689	ND	ND	ND	.
rs719569 <sup>†</sup>	cg17830980 <sup>§</sup>	$3.7 \times 10^{-39}$	-0.482	ND	ND	ND	.
rs719569 <sup>†</sup>	cg00637047	$6.9 \times 10^{-30}$	-0.278	ND	ND	ND	.
rs719569 <sup>†</sup>	cg00409905	$3.7 \times 10^{-28}$	-0.406	ND	ND	ND	.
rs719569 <sup>†</sup>	cg01217720 <sup>§</sup>	$2.3 \times 10^{-18}$	-0.326	ND	ND	ND	.
rs719569 <sup>†</sup>	cg12163508	$4.1 \times 10^{-18}$	-0.362	ND	ND	ND	.
rs719569 <sup>†</sup>	cg23533926 <sup>§</sup>	$4.7 \times 10^{-17}$	-0.259	ND	ND	ND	.
rs719569 <sup>†</sup>	cg18963800	$4.8 \times 10^{-15}$	-0.326	ND	ND	ND	.
rs719569 <sup>†</sup>	cg27523141 <sup>§</sup>	$1.7 \times 10^{-14}$	0.269	ND	ND	ND	.
rs719569 <sup>†</sup>	cg26666804 <sup>§</sup>	$3.2 \times 10^{-14}$	-0.287	ND	ND	ND	.
rs719569 <sup>†</sup>	cg20499290 ( <i>ZNF33BP1</i> )	$4.6 \times 10^{-17}$	0.340	0.774	0.394	Hypermethylation	0.48
rs12256543 <sup>†</sup>	cg20499290 <sup>§</sup> ( <i>ZNF33BP1</i> )	$1.2 \times 10^{-14}$	-0.318	0.774	0.394	Hypermethylation	2.07
rs12256543 <sup>†</sup>	cg25427524	$4.0 \times 10^{-112}$	0.836	ND	ND	ND	.
rs12256543 <sup>†</sup>	cg02535924	$6.8 \times 10^{-66}$	-0.692	ND	ND	ND	.
rs12256543 <sup>†</sup>	cg17830980 <sup>§</sup>	$2.3 \times 10^{-32}$	0.446	ND	ND	ND	.
rs12256543 <sup>†</sup>	cg00637047	$4.9 \times 10^{-26}$	0.263	ND	ND	ND	.
rs12256543 <sup>†</sup>	cg00409905	$1.4 \times 10^{-24}$	0.385	ND	ND	ND	.
rs12256543 <sup>†</sup>	cg12163508	$2.6 \times 10^{-24}$	0.427	ND	ND	ND	.
rs12256543 <sup>†</sup>	cg01217720 <sup>§</sup>	$7.2 \times 10^{-23}$	0.370	ND	ND	ND	.
rs12256543 <sup>†</sup>	cg23533926 <sup>§</sup>	$5.6 \times 10^{-22}$	0.299	ND	ND	ND	.
rs12256543 <sup>†</sup>	cg18963800	$2.3 \times 10^{-20}$	0.387	ND	ND	ND	.
rs12256543 <sup>†</sup>	cg26666804 <sup>§</sup>	$9.5 \times 10^{-20}$	0.346	ND	ND	ND	.
rs12256543 <sup>†</sup>	cg04469686 <sup>§</sup>	$6.5 \times 10^{-16}$	0.342	ND	ND	ND	.
rs12256543 <sup>†</sup>	cg25373794 <sup>§</sup>	$2.1 \times 10^{-15}$	0.333	ND	ND	ND	.
rs12256543 <sup>†</sup>	cg25951256	$3.6 \times 10^{-14}$	0.328	ND	ND	ND	.
rs7195089 <sup>‡</sup>	cg05797001	$1.1 \times 10^{-25}$	0.949	ND	ND	ND	.
rs7195089 <sup>‡</sup>	cg07982935	$1.7 \times 10^{-21}$	-0.864	ND	ND	ND	.
rs7195089 <sup>‡</sup>	cg27232078 ( <i>CHST5</i> )	$6.1 \times 10^{-15}$	0.782	0.851	0.592	Hypermethylation	5.80
rs2233805 <sup>‡</sup>	cg27232078 ( <i>CHST5</i> )	$1.4 \times 10^{-15}$	0.814	0.851	0.592	Hypermethylation	4.77
rs2233805 <sup>‡</sup>	cg05797001	$2.1 \times 10^{-26}$	0.980	ND	ND	ND	.
rs2233805 <sup>‡</sup>	cg07982935	$7.2 \times 10^{-23}$	-0.908	ND	ND	ND	.

ALL=acute lymphoblastic leukaemia, ND=no data, SNP=single nucleotide polymorphism.

\* meQTL P value (statistical significance threshold  $\leq 5 \times 10^{-14}$ ).<sup>[37]</sup>

<sup>†</sup> Sex-specific variants based on statistical significance.

<sup>‡</sup> Sex-specific variants based on effect size.

<sup>§</sup> Trans-meQTL (target CpG sites are on chromosomes different from the chromosome the SNP is located, or more than 500 kb away from the SNP on the same chromosome).<sup>[37]</sup> Gene names and odds ratios are shown only for the SNPs with statistically significant methylation differences in ALL.

microRNA binding site in 3' UTR. To gain further insight into *RASSF2* function, we obtained the list of experimentally confirmed target gene list for mir-19a/19b (n=298) from NPinter database, and subjected this list to GSEA on DAVID. The highest fold enrichment (12.4) was observed for RAS association category, which was also the statistically most significant (false discovery rate [FDR]=0.004). Apoptosis was also one of the most highly significant categories (fold enrichment=3.5; FDR=0.007). Thus, the only microRNA that had an experimentally confirmed physical interaction with *RASSF2* had targets cumulatively involved in RAS signaling and apoptosis (mir-19a/19b belongs to the mir-17-92 cluster).

The second ranking SNP rs23127 (OR<sub>interaction</sub>=3.0), located in the genes *PROSER3/HSPB6*, yielded a high risk for males compared with females for childhood ALL (Table 2).

Our analysis suggested that rs23127 might have multiple regulatory functions as it affects the expression level of several genes (*COX6B1*;  $P=2.2 \times 10^{-6}$ , *UPK1A*;  $P=1.2 \times 10^{-7}$  and *U2AF1LA*;  $P=3.1 \times 10^{-9}$ ) (Supplementary Table 3, <http://links.lww.com/MD/B377>) and is also located in an active promoter region (RegulomeDB=2b; CADD=7.8; DANN=0.71). Another top ranking SNP, rs798292, is associated with expression of *KAT7* (K(lysine) acetyltransferase 7), a histone acetyltransferase that represses androgen receptor-mediated transcription in lymphoblastoid cells<sup>[36]</sup> (Supplementary Table 3, <http://links.lww.com/MD/B377>). Results ranked by statistical significance showed more eQTLs in lymphoblastoid cell lines in comparison to the results based on effect size (Supplementary Table 3, <http://links.lww.com/MD/B377>).

Table 3 and Supplementary Table 2 (<http://links.lww.com/MD/B376>) show the results based on the highest effect sizes. Two statistically correlated SNPs ( $r^2 = 1$ ), rs12722042 (CADD = 16.02 and DANN = 1) and rs12722039 (CADD = 5.02 and DANN = 0.49), from the *HLA-DQA1* (major histocompatibility complex, class II, DQ alpha 1) gene and a SNP, rs11992342, from the *ADAM28* (ADAM metalloproteinase domain 28) region yielded the highest effect sizes ( $OR_{interaction} > 14$ ;  $P \leq 0.01$ ) for sex-specific results. Both *HLA-DQA1* SNPs were missense variants and marked by several histone modification marks, such as Histone-3 lysine-4 monomethylation (H3K4me1), Histone-3 lysine-4 trimethylation (H3K4me3), Histone-3 lysine-9 acetylation (H3K9ac), and Histone-3 lysine-27acetylation (H3K27ac) indicating the location within an active promoter site. When we examined whether there are crucial TFBSs in the vicinity of these SNPs located at chromosome 6 positions 32,605,284 and 32,605,309 (hg19 coordinates), Swiss Regulon browser indicated that there was an androgen receptor binding site within 100 bp of these SNPs (32,605,225 to 32,605,2546). *ADAM28* rs11992342 maps to an active enhancer region, and affects binding affinity of several TFs of STAT family. Top ranking 100 results based on OR included associations with more missense variants than the results based on *P* values (34 vs 2) (Supplementary Tables 1 and 2, <http://links.lww.com/MD/B375>, <http://links.lww.com/MD/B376>). Our results predicted several of these missense variants may have deleterious effects on final protein structure (Supplementary Table 4, <http://links.lww.com/MD/B378>). Most of the identified sex-specific SNPs were located in cis-regulatory elements, such as promoters and enhancers or may have eQTL effects (Supplementary Tables 1 and 2, <http://links.lww.com/MD/B375>, <http://links.lww.com/MD/B376>).

Our mQTLdb screening results showed that several variants were meQTLs at birth, during childhood and adolescence, as well as during pregnancy (Supplementary Table 5, <http://links.lww.com/MD/B379>). We examined the involvement of the CpG sites linked to our GWAS associations in B-cell differentiation and leukemogenesis by using the data provided by Kulis et al.<sup>[50]</sup> A total of 24 variants were reported to be pivotal for B-lymphocyte differentiation and their target CpG sites found to be either hypermethylated or hypomethylated in ALL (Table 4). Most notably, the top ranking SNP rs4813720 is an meQTL for the CpG island cg22485289 within *RASSF2*. Both *HLA-DQA1* SNPs (rs12722042 and rs12722039) are meQTLs for the CpG island cg24593918 within *HLA-DQB1*.

GWAS3D analysis for the top 100 ranking sets of SNPs unraveled a number of long-range interactions between the regions of SNP locations and other genes, some of which being on different chromosomes (Supplementary Figures 2 and 3, <http://links.lww.com/MD/B374>). GWAS3D reported 84 variants with TF binding affinity changes or regulatory signals based on the GM12878 cell line and HapMap CEU population for 100 statistically most significant results. A total of 66 variants have been detected affecting long-range interactions (Supplementary Figure 2, <http://links.lww.com/MD/B374>). Cumulatively, GWAS3D results suggested a potential role for STAT and MYC TFs in sex-differences in childhood ALL risk. Among the top 100 results ranked by the effect size, GWAS3D analysis showed that 68 of the variants were associated with regulatory signals and TF binding affinity changes on the GM12878 cell line and HapMap CEU population. Long-range interactions were noted for 60 variants (Supplementary Figure 3, <http://links.lww.com/MD/B374>).

As shown in Table 5, in all ALL subtypes examined in the MILE study, *RASSF2* expression was lower than controls, and

**Table 5**  
Expression differences in mir-17-92, *RASSF2*, and *MYC* in acute lymphoblastic leukemia subtypes in the MILE study.

Gene Symbol	P value (disease class) <sup>†</sup>	ALL with hyperdiploid karyotype		ALL with t (12;21)		ALL with t (1;19)		Pro-B-ALL with t (11q23) / MLL		T-ALL		c-ALL / Pre-B-ALL with t (9;22)		c-ALL / Pre-B-ALL without t (9;22)		Mature B-ALL with t (8;14)	
		P value <sup>‡</sup>	Ratio <sup>‡</sup>	P value	Ratio	P value	Ratio	P value	Ratio	P value	Ratio	P value	Ratio	P value	Ratio	P value	Ratio
<i>MIR17 cluster (MIR17HG)</i>	$9.9 \times 10^{-68}$	$2.8 \times 10^{-6}$	1.78	$2.5 \times 10^{-25}$	3.17	0.02	1.35	$2.7 \times 10^{-7}$	1.71	$5.8 \times 10^{-10}$	1.71	$6.7 \times 10^{-13}$	1.94	$4.4 \times 10^{-16}$	1.97	$1.6 \times 10^{-5}$	2.03
<i>RASSF2</i>	$5.6 \times 10^{-167}$	$1.9 \times 10^{-5}$	0.64	$2.4 \times 10^{-13}$	0.50	0.03	0.79	$3.9 \times 10^{-9}$	0.59	$6.8 \times 10^{-80}$	0.23	$3.4 \times 10^{-17}$	0.51	$3.5 \times 10^{-23}$	0.49	0.11	0.77
<i>MYC</i>	$3.1 \times 10^{-55}$	0.30	1.17	$3.2 \times 10^{-6}$	0.53	0.77	0.96	$1.8 \times 10^{-8}$	2.08	0.02	0.78	0.02	0.77	0.36	0.91	$1.9 \times 10^{-8}$	3.75

\* MIR17 cluster consists of MIR17, MIR18A, MIR19A, MIR19B1, MIR20A, MIR92A1.

<sup>†</sup> Heterogeneity in expression levels among all 17 disease classes included in the MILE study.

<sup>‡</sup> All comparisons (P value and ratio) are against nonleukemia and healthy bone marrow controls.

mir-17-92 levels were higher with statistical significance varying from  $P=0.02$  to  $6.8 \times 10^{-80}$ . The statistically most significant change in *RASSF2* was in T-ALL with the expression ratio to controls being 0.23 (mir-17-92 showed an expression ratio of 1.71 in T-ALL). The statistically most significant change in mir-17-92 was in ALL with t(12;21) with the expression ratio to controls being 3.17 (*RASSF2* showed an expression ratio of 0.50 in the same ALL subtype). In all subtypes, *RASSF2* and mir-17-92 expression levels showed an inverse correlation (Table 5). The expression levels of *MYC* did not appear to correlate with mir-17-92 levels except in pro-B and mature B-ALL subtypes (Table 5). While the strong inverse correlation between *RASSF2* and mir-17-92 confirmed the expected relationship between them, the lack of a correlation between *MYC* and mir-17-92 suggested that mir-17-92 increase in ALL is not exclusively caused by *MYC*, but may be due to genomic amplifications as observed in other malignancies.<sup>[45]</sup>

#### 4. Discussion

This is the first GWAS designed to identify sex-specific childhood ALL risk markers. As a second exploratory approach, we also analyzed results based on OR, to examine clinically meaningful results that may not have reached the strict statistical significance due to their lower frequencies. These results are free from multiple comparison issues, as each permutation on each SNP assesses the role of chance.

The statistically most significant association was with an intronic SNP in *RASSF2*, which is a novel tumor suppressor gene and a member of the RAS family which regulates a wide range of biological processes, including KRAS signaling.<sup>[46,47]</sup> It induces apoptosis and cell cycle arrest, shows frequent methylation in several cancers, and rs4813720 correlates with *RASSF2* expression levels.<sup>[48]</sup> *RASSF2* ablation down regulates genes involved in the immune response, hematological development, as well as genes activating nuclear factor (NF)- $\kappa$ B signaling.<sup>[46]</sup>

*RASSF2* has emerged as a candidate gene involved in sex-specific modification of risk for childhood ALL in the present study for the first time. This result is biologically plausible. *RASSF2* is a tumor suppressor gene via its inhibitory effect on the proto-oncogene *KRAS*.<sup>[43]</sup> *KRAS* is one of the most frequently mutated proto-oncogenes in childhood ALL.<sup>[44,49]</sup> The top ranking sex-specific risk marker for childhood ALL, rs4813720, correlates with *RASSF2* expression level,<sup>[36]</sup> as well as the methylation levels in a key CpG site cg22485289 within the promoter of *RASSF2* at birth and childhood.<sup>[37]</sup> This particular CpG site is one of the key sites found to be hypomethylated in childhood ALL compared with pre-B cells.<sup>[50]</sup> Thus, rs4813720 appears to be involved in the prevention of childhood ALL in males via maintaining the expression levels of tumor suppressive *RASSF2* in pre-B cells presumably via a methylation-related mechanism. Linkage of DNA methylation quantitative trait loci to human cancer risk is already well documented,<sup>[48]</sup> and our results represent yet another example.

The sex effect in the prevention of childhood ALL by *RASSF2* expression may also be biologically plausible. The key to the sex effect may be the events upstream of *RASSF2*. The miR-17-92 cluster, which is in an amplified genomic region in human malignant B-cell lymphomas, has been shown to be an oncomiRNA also in *c-Myc*-induced lymphomagenesis in mice.<sup>[51]</sup> mir-17-92 also plays a major role in normal B-cell development.<sup>[52,53]</sup> In an experimental study, *RASSF2* has been found to be a target gene for the mir-92 polycistron.<sup>[54]</sup> Our

bioinformatics work also confirmed a physical interaction with one of the micro RNAs that derive from mir-17-92 polycistron, mir-19a/19b, and revealed a predicted binding site for it (see Results). Crucially, estrogen administration increases mir-17-92 levels via *MYC* overexpression<sup>[55,56]</sup> and downregulates *RASSF2* expression.<sup>[57]</sup> Thus, in addition to the already known involvement of sex hormones in the gender effect in cancer,<sup>[58]</sup> we propose a novel mechanism for childhood ALL: estrogen exposure increases the oncogenic microRNA species mir-19a/19b levels, which in turn downregulates *RASSF2* (as well as another tumor suppressor *PTEN*<sup>[59]</sup>). Downregulation of *RASSF2* abolishes *KRAS* inhibition, and the *KRAS* oncogene contributes to childhood ALL development. Males are already less susceptible to this mechanism due to lesser exposure to estrogen, as well as due to the presence of binding sites to Y chromosome-linked transcription factor SRY,<sup>[47]</sup> and are further protected if they possess the minor allele of rs4813720, which increases *RASSF2* expression levels. If experimentally confirmed, this would be the first demonstration of the mechanism of a sexually antagonistic association of a SNP with cancer susceptibility. Although sex hormone levels are very low during childhood in both males and females, programming of autosomal gene expression by sex hormones during prenatal development or during the temporary androgen surge in early infancy (called mini-puberty) is a possibility. Mini-puberty is particularly interesting as inter individual variability in sex hormone levels, which may rise to the puberty levels but temporarily, may be very remarkable.<sup>[60,61]</sup> Unfortunately, there are no studies on the long-term effects of these sex hormone exposures in early infancy on biological systems although behavioral studies continue to show the relevance of this exposure.<sup>[60,62]</sup>

Having a marker that is associated with prevention for childhood ALL in males has clinical importance. Males develop childhood ALL more frequently, have a higher relapse rate, and worse prognosis.<sup>[4]</sup> Due to having clinically more aggressive form of the disease, they also receive more intensive treatment resulting in higher toxicity. The marker is within *RASSF2* and acts by increasing its expression, which in turn, binds to and inactivates *KRAS*. *KRAS* is frequently mutated in childhood ALL<sup>[44,49]</sup> and mutant *KRAS* worsens the prognosis.<sup>[49]</sup> Thus, any pharmacological intervention to increase the expression of *RASSF2* should be beneficial for male patients with childhood ALL, especially for those with *KRAS* mutations, to counter the deleterious effects of mutant *KRAS*.

Examination of associations with the highest odds ratios identified a pair of HLA region SNPs. The *HLA-DQA1* SNPs (rs12722042 and rs12722039) belong to *DQA1\*01*, confirming the previously reported male-specific association with *DQA1\*01*, and supporting the proposed infection-related etiology in childhood ALL risk for males.<sup>[63]</sup> Both *HLA-DQA1* SNPs are located in an active promoter region and showed eQTL effects on the *HLA-DQB1* gene. These SNPs have regulatory effects on gene expression rather than on protein structure. Intriguingly, the *HLA-DQA1* SNPs are in close proximity (<100 bp) of an androgen receptor binding site. This observation may be relevant in their risk associations with childhood ALL in males. The SNP rs35597309, correlated statistically with rs12722042 ( $r^2=0.97$ ), has shown a risk association with esophageal squamous cell carcinoma in a Chinese population<sup>[64]</sup> (esophageal carcinoma has a high male-to-female ratio).

The validity of the case-only design depends on the independence of exposure and genotype.<sup>[24]</sup> Departures from this

independence may affect the results. Such an association would be invalid due to the violation of the major assumption of case-only approach. In the case of gender, it seems unlikely to have different genotype frequencies in autosomal chromosomes between males and females in the healthy population.<sup>[65]</sup> Conforming to the assumptions of the case-control design still does not make the results valid until replicated by a second independent study. The lack of a previously observed association of *RASSF2* SNPs with childhood ALL does not argue against the validity of our result. This is most likely due to cancellation of associations in opposite directions in males and females when the analysis is performed on the overall sample. None of the previous childhood ALL GWAS performed sex-specific analyses. Despite the biological plausibility of our results, given the limited sample size of our study and lack of replication, it is important to reexamine these results in an independent study before proceeding to functional studies. These results cannot be generalized in any other ethnic population, as all of these samples were non-Hispanic whites.

In conclusion, our results suggest that novel sex-specific risk variants for childhood ALL exist. Functional analyses suggest that most variants (either direct effect or through LD) have regulatory effects, which increases the likelihood of causal associations. For instance, the statistically most significant association rs4813720 correlates with *RASSF2* expression and may play a significant role in childhood ALL etiology. Our results also confirm the previously observed male-specific association with *DQA1\*01*. While ranking results by OR is not a traditional approach for GWAS, this exploratory approach yielded several missense variants with effects on protein function. The statistically most significant association was with a SNP within *RASSF2*, which interacts with *KRAS*. Given the difficulties of developing drugs to inactivate *KRAS* directly,<sup>[66]</sup> the demonstration of the effect of *RASSF2* in prevention from childhood ALL may even offer a new target for drug development efforts. Feasibility of countering the downstream effects of mir-17-92 by pharmacological manipulation has already been shown.<sup>[67]</sup> Prenatal programming by sex hormones, if confirmed, may shed some light on the mechanism of the differential risk with childhood ALL. These preliminary results provide a foundation for further replication and functional studies to examine the genetic basis of sex-differential in childhood ALL risk. Future studies should include functional and genetic replication of the *RASSF2* association, particularly in case series with known *KRAS* mutation status. Given the well-established involvement of the oncogenic mir-17-92 in its development and the more exaggerated male predominance, childhood non-Hodgkin lymphoma should also be examined for *RASSF2* associations.<sup>[67,68]</sup>

## References

- [1] Howlander N, Noone AM, Krapcho M, et al (eds). SEER Cancer Statistics Review, 1975-2012, National Cancer Institute. Bethesda, MD, Available at: [http://seer.cancer.gov/csr/1975\\_2012/](http://seer.cancer.gov/csr/1975_2012/), based on November 2014 SEER data submission, posted to the SEER web site, April 2015 (accessed May 31, 2016).
- [2] Spector LG, Pankratz N, Marcotte EL. Genetic and nongenetic risk factors for childhood cancer. *Pediatr Clin North Am* 2015;62:11-25.
- [3] Cook MB, Dawsey SM, Freedman ND, et al. Sex disparities in cancer incidence by period and age. *Cancer Epidemiol Biomarkers Prev* 2009;18:1174-82.
- [4] Dorak MT, Karpuzoglu E. Gender differences in cancer susceptibility: an inadequately addressed issue. *Front Appl Genet Epidemiol* 2012;3:268.
- [5] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016;66:7-30.
- [6] Mulder RL, Hudson MM, Skinner R, et al. Health problems in survivors of childhood cancer: the need for international collaboration in long-term follow-up care. *Future Oncol* 2013;9:1667-70.
- [7] Randall JC, Winkler TW, Kutalik Z, et al. Sex-stratified Genome-wide Association Studies Including 270,000 Individuals Show Sexual Dimorphism in Genetic Loci for Anthropometric Traits. *PLoS Genet* 2013;9:e1003500.
- [8] Gilks WP, Abbott JK, Morrow EH. Sex differences in disease genetics: evidence, evolution, and detection. *Trends Genet* 2014;30:453-63.
- [9] Do TN, Ucisik-Akkaya E, Davis CF, et al. An intronic polymorphism of IRF4 gene influences gene transcription in vitro and shows a risk association with childhood acute lymphoblastic leukemia in males. *Biochim Biophys Acta* 2010;1802:292-300.
- [10] Morrison BA, Ucisik-Akkaya E, Flores H, et al. Multiple sclerosis risk markers in HLA-DRA, HLA-C, and IFNG genes are associated with sex-specific childhood leukemia risk. *Autoimmunity* 2010;43:690-7.
- [11] Kennedy AE, Kamdar KY, Lupu PJ, et al. Genetic markers in a multi-ethnic sample for childhood acute lymphoblastic leukemia risk. *Leuk Lymphoma* 2015;56:169-74.
- [12] Healy J, Richer C, Bourgey M, et al. Replication analysis confirms the association of ARID5B with childhood B-cell acute lymphoblastic leukemia. *Haematologica* 2010;95:1608-11.
- [13] Wang SL, Zhao H, Zhou B, et al. Polymorphisms in ERCC1 and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population. *Leuk Res* 2006;30:1341-5.
- [14] Xu H, Yang W, Perez-Andreu V, et al. Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations. *J Natl Cancer Inst* 2013;105:733-42.
- [15] Trevino LR, Yang W, French D, et al. Germline genomic variants associated with childhood acute lymphoblastic leukemia. *Nat Genet* 2009;41:1001-5.
- [16] Papaemmanuil E, Hosking FJ, Vijayakrishnan J, et al. Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. *Nat Genet* 2009;41:1006-10.
- [17] Loisel DA, Tan Z, Tisler CJ, et al. IFNG genotype and sex interact to influence the risk of childhood asthma. *J Allergy Clin Immunol* 2011;128:524-31.
- [18] Myers RA, Scott NM, Gauderman WJ, et al. Genome-wide interaction studies reveal sex-specific asthma risk alleles. *Hum Mol Genet* 2014;23:5251-9.
- [19] Yao C, Joeannes R, Johnson AD, et al. Sex- and age-interacting eQTLs in human complex diseases. *Hum Mol Genet* 2014;23:1947-56.
- [20] Dimas AS, Nica AC, Montgomery SB, et al. Sex-biased genetic effects on gene regulation in humans. *Genome Res* 2012;22:2368-75.
- [21] Jansen R, Batista S, Brooks AI, et al. Sex differences in the human peripheral blood transcriptome. *BMC Genom* 2014;15:33.
- [22] Liu LY, Schaub MA, Sirota M, et al. Sex differences in disease risk from reported genome-wide association study findings. *Hum Genet* 2012;131:353-64.
- [23] Orozco G, Ioannidis JP, Morris A, et al. Sex-specific differences in effect size estimates at established complex trait loci. *Int J Epidemiol* 2012;41:1376-82.
- [24] Clayton D, McKeigue PM. Epidemiological methods for studying genes and environmental factors in complex diseases. *Lancet* 2001;358:1356-60.
- [25] Anderson CA, Pettersson FH, Clarke GM, et al. Data quality control in genetic case-control association studies. *Nat Protoc* 2010;5:1564-73.
- [26] Devlin B, Bacanu SA, Roeder K. Genomic control to the extreme. *Nat Genet* 2004;36:1129-30.
- [27] Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 2010;38:e164.
- [28] Chelala C, Khan A, Lemoine NR. SNPnexus: a web database for functional annotation of newly discovered and public domain single nucleotide polymorphisms. *Bioinformatics* 2009;25:655-61.
- [29] Kircher M, Witten DM, Jain P, et al. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet* 2014;46:310-5.
- [30] Schaub MA, Boyle AP, Kundaje A, et al. Linking disease associations with regulatory information in the human genome. *Genome Res* 2012;22:1748-59.
- [31] Ward LD, Kellis M. HaploReg v4: systematic mining of putative causal variants, cell types, regulators and target genes for human complex traits and disease. *Nucleic Acids Res* 2016;44:D877-81.
- [32] Arnold M, Raffler J, Pfeuffer A, et al. SNIIPA: an interactive, genetic variant-centered annotation browser. *Bioinformatics* 2015;31:1334-6.
- [33] Guo L, Du Y, Qu S, et al. rVarBase: an updated database for regulatory features of human variants. *Nucleic Acids Res* 2016;44:D888-93.

- [34] Li MJ, Wang LY, Xia Z, et al. GWAS3D: detecting human regulatory variants by integrative analysis of genome-wide associations, chromosome interactions and histone modifications. *Nucleic Acids Res* 2013;41:W150–8.
- [35] Gamazon ER, Zhang W, Konkashbaev A, et al. SCAN: SNP and copy number annotation. *Bioinformatics* 2010;26:259–62.
- [36] Westra HJ, Peters MJ, Esko T, et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. *Nat Genet* 2013;45:1238–43.
- [37] Gaunt TR, Shihab HA, Hemani G, et al. Systematic identification of genetic influences on methylation across the human life course. *Genome Biol* 2016;17:61.
- [38] Pachkov M, Balwiercz PJ, Arnold P, et al. SwissRegulon, a database of genome-wide annotations of regulatory sites: recent updates. *Nucleic Acids Res* 2013;41:D214–20.
- [39] Huang da W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. *Nucleic Acids Res* 2009;37:1–3.
- [40] Hao Y, Wu W, Li H, et al. NPInter v3.0: an upgraded database of noncoding RNA-associated interactions. *Database (Oxford)* 2016;pii: baw2057.
- [41] Agarwal V, Bell GW, Nam JW, et al. Predicting effective microRNA target sites in mammalian mRNAs. *Elife* 2015;4:e05005.
- [42] Haferlach T, Kohlmann A, Wiczorek L, et al. Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. *J Clin Oncol* 2010;28:2529–37.
- [43] Richter AM, Pfeifer GP, Dammann RH. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. *Biochim Biophys Acta* 2009;1796:114–28.
- [44] Case M, Matheson E, Minto L, et al. Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. *Cancer Res* 2008;68:6803–9.
- [45] Volinia S, Galasso M, Costinean S, et al. Reprogramming of miRNA networks in cancer and leukemia. *Genome Res* 2010;20:589–99.
- [46] Song H, Kim H, Lee K, et al. Ablation of *Rassf2* induces bone defects and subsequent haematopoietic anomalies in mice. *EMBO J* 2012;31:1147–59.
- [47] Volodko N, Gordon M, Salla M, et al. RASSF tumor suppressor gene family: biological functions and regulation. *FEBS Lett* 2014;588:2671–84.
- [48] Heyn H, Sayols S, Moutinho C, et al. Linkage of DNA methylation quantitative trait loci to human cancer risk. *Cell Rep* 2014;7:331–8.
- [49] Irving J, Matheson E, Minto L, et al. Ras pathway mutations are prevalent in relapsed childhood acute lymphoblastic leukemia and confer sensitivity to MEK inhibition. *Blood* 2014;124:3420–30.
- [50] Kulis M, Merkel A, Heath S, et al. Whole-genome fingerprint of the DNA methylome during human B cell differentiation. *Nat Genet* 2015;47:746–56.
- [51] He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. *Nature* 2005;435:828–33.
- [52] Ventura A, Young AG, Winslow MM, et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. *Cell* 2008;132:875–86.
- [53] Lai M, Gonzalez-Martin A, Cooper AB, et al. Regulation of B-cell development and tolerance by different members of the miR-17~92 family microRNAs. *Nat Commun* 2016;7:12207.
- [54] Li Z, Luo RT, Mi S, et al. Consistent deregulation of gene expression between human and murine MLL rearrangement leukemias. *Cancer Res* 2009;69:1109–16.
- [55] Castellano L, Giamas G, Jacob J, et al. The estrogen receptor- $\alpha$ -induced microRNA signature regulates itself and its transcriptional response. *Proc Natl Acad Sci U S A* 2009;106:15732–7.
- [56] Wang C, Mayer JA, Mazumdar A, et al. Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. *Mol Endocrinol* 2011;25:1527–38.
- [57] Ren CE, Zhu X, Li J, et al. Microarray analysis on gene regulation by estrogen, progesterone and tamoxifen in human endometrial stromal cells. *Int J Mol Sci* 2015;16:5864–85.
- [58] Clocchiatti A, Cora E, Zhang Y, et al. Sexual dimorphism in cancer. *Nat Rev Cancer* 2016;16:330–9.
- [59] Olive V, Bennett MJ, Walker JC, et al. miR-19 is a key oncogenic component of mir-17-92. *Genes Dev* 2009;23:2839–49.
- [60] Alexander GM, Wilcox T, Farmer ME. Hormone-behavior associations in early infancy. *Horm Behav* 2009;56:498–502.
- [61] Tomlinson C, Macintyre H, Dorrian CA, et al. Testosterone measurements in early infancy. *Arch Dis Child Fetal Neonatal Ed* 2004;89:F558–9.
- [62] Hines M, Spencer D, Kung KT, et al. The early postnatal period, mini-puberty, provides a window on the role of testosterone in human neurobehavioural development. *Curr Opin Neurobiol* 2016;38:69–73.
- [63] Taylor GM, Dearden S, Payne N, et al. Evidence that an HLA-DQA1-DQB1 haplotype influences susceptibility to childhood common acute lymphoblastic leukaemia in boys provides further support for an infection-related aetiology. *Br J Cancer* 1998;78:561–5.
- [64] Kong KL, Kwong DL, Fu L, et al. Characterization of a candidate tumor suppressor gene uroplakin 1A in esophageal squamous cell carcinoma. *Cancer Res* 2010;70:8832–41.
- [65] Boraska V, Jeroncic A, Colonna V, et al. Genome-wide meta-analysis of common variant differences between men and women. *Hum Mol Genet* 2012;21:4805–15.
- [66] McCormick F. K-Ras protein as a drug target. *J Mol Med (Berl)* 2016;94:253–8.
- [67] Jin HY, Lai M, Xiao C. microRNA-17~92 is a powerful cancer driver and a therapeutic target. *Cell Cycle* 2014;13:495–6.
- [68] Jin HY, Oda H, Lai M, et al. MicroRNA-17~92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. *EMBO J* 2013;32:2377–91.